<DOC>
	<DOCNO>NCT00046228</DOCNO>
	<brief_summary>The purpose study determine whether abciximab give combination reteplase , patient coronary intervention ( standard treatment catheter insert heart artery get blood flow past clot ) , safe effective treatment heart attack compare abciximab give coronary intervention .</brief_summary>
	<brief_title>A Study Abciximab Reteplase When Administered Prior Catherization After Myocardial Infarction ( Finesse )</brief_title>
	<detailed_description>The purpose medical research study determine whether abciximab give combination reteplase , patient coronary intervention ( standard treatment catheter insert heart artery get blood flow past clot ) , safe effective treatment heart attack compare abciximab give coronary intervention . This medical research study also help determine combination abciximab reduce dose reteplase decrease risk death , reduce complication heart attack 90 day compare abciximab alone standard treatment . Patients receive either abciximab reteplease abciximab alone . Safety evaluation perform specify interval throughout study consist laboratory test , vital sign ( blood pressure ) , physical examination occurrence severity adverse event well study specific procedure . Patients receive either abciximab reteplease abciximab placebo vein arm 12 hour .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<mesh_term>Reteplase</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Patients prolong , continuous ( last least 20 minute ) sign symptoms A heart attack eliminate nitrate onset within 6 hour randomization , confirmation Electrocardiogram Low risk clinical presentation patient undergoing catherization within 4 hour qualify Electrocardiogram</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Myocardial infarction</keyword>
	<keyword>percutaneous coronary intervention</keyword>
	<keyword>abciximab</keyword>
	<keyword>reteplase</keyword>
	<keyword>safety efficacy</keyword>
</DOC>